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ABSTRACT 
 
Objective: The objective of this selective evidence-based medicine (EBM) review is to 
determine whether bovine lactoferrin is effective in preventing diarrhea in infants and toddlers. 
 
Study design: Review of three English-language primary randomized controlled trials published 
between 2007 and 2016. 
 
Data sources: Three double-blind controlled trials comparing bovine lactoferrin to placebo were 
found using PubMed. 
 
Outcomes measured: Incidence and incidence rate of diarrhea in episodes/child/year were 
measured using the information provided by the caregivers and the healthcare records obtained 
from a hospital or clinic.  
 
Results: King et al. found that there was no statistically significant difference in incidence of 
diarrhea between the infants taking bovine lactoferrin (1.31 episodes/infant/year) versus placebo 
(1.35 episodes/infant/year) in a 0- to 12-months-old age group. Similarly, Ochoa et al. 
determined no statistically significant difference in diarrhea occurrence between children who 
received a bovine lactoferrin supplement (5.43 episodes/child/year) and the children who 
received placebo (5.15 episodes/child/year) in a 12- to 18-months-old age group (p = 0.375). In 
contrast, Chen et al. found a significantly lower incidence rate of diarrhea in infants after 
exposure to bovine lactoferrin as compared to placebo (rate ratio of 0.32 with p < 0.05) in a 4- to 
6-months-old age group. 
 
Conclusion: The evidence regarding whether bovine lactoferrin is effective in preventing 
diarrhea in infants and toddlers is conflicting. It appeared to be clinically effective in 4- to 6-
months-old infants who were followed over a 3-months period, but had shown no effect in 0- to 
12- and 12- to 18-months-old infants and toddlers who were followed for 12 and 6 months, 
respectively. Therefore, it is possible that the effectiveness of bovine lactoferrin demonstrated by 
Chen et al. could have been influenced in some way by the short duration of the study and by the 
especially narrow age group. 
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Introduction: 
 Diarrhea is the passage of liquid or loose stools 3 or more times per day.1 Worldwide, it 
is a leading cause of death among children younger than 5 years old and it carries a significant 
morbidity with substantial negative effects on population health.2 In the United States, infectious 
diarrhea is most commonly caused by viral pathogens, such as rotavirus or norovirus and 
accounts for greater than 1.5 million outpatient visits and approximately 200,000 hospitalizations 
each year.3,4 In 2015 in the United States, 140,000 cases of diarrheal disease were reported in 
children younger than 5 years old, with 293 deaths.5 The estimated direct medical cost of 
diarrheal-disease-related hospitalizations in the United States in 2013 was $226 million with 
70,553 hospitalizations in children younger than 5 years old.6 
There is a number of etiologies that can cause diarrhea, including infectious ones, such as 
enteric adenovirus of serotypes 40 and 41, Aeromaons spp, Entamoeba histolytica, 
Campylobacter spp enteritis, cryptosporidiosis, typical enteropathogenic Escherichia coli, 
enterotoxigenic E. coli, norovirus, non-typhoidal Salmonella spp, rotaviral enteritis, shigellosis, 
cholera, and Clostridium difficile. Diarrhea can quickly lead to dehydration, and the following 
physical-exam findings may suggest its occurrence: tachycardia, delayed capillary refill, dry 
mucous membranes, decrease in urine output, reduced skin turgor, and decrease in body weight 
by 5% or more. The following methods of diarrheal prevention are currently recommended by 
the World Health Organization: having access to clean drinking water and using improved 
sanitation; promoting good hand, personal, and food hygiene; educating about the spread of 
infection; emphasizing the importance of exclusive breastfeeding for the first 6 months of an 
infant’s life; and receiving rotavirus vaccine.1  
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Lactoferrin (LF) is a bilobed, iron-binding glycoprotein found in human breast milk, 
saliva, tears, intestinal and genital secretions, and secondary granules of neutrophils.7,8 It has 
antimicrobial, anti-inflammatory, and immunomodulatory activities and has been shown to 
decrease virulence of enteropathogens in vitro.7 The antimicrobial activity of LF includes 
sequestering iron that is necessary for bacterial growth and disrupting the integrity of the 
bacterial cell membrane.8 Human LF and bovine lactoferrin (bLF) have similar structures, 
functions, and bioactivity, and bLF has been shown to be safe in infants.8 Introducing bLF as a 
supplement for infants and toddlers may be an effective preventative measure for common 
diarrheal diseases. 
Objective:  
The objective of this selective evidence-based medicine (EBM) review is to determine 
whether bLF is effective in preventing diarrhea in infants and toddlers. 
Methods:  
The research was done by the author of this EBM review, and the databases used were 
PubMed and Cochrane Library. The key words used in the searches were “bovine lactoferrin” 
and “infant.” The English-language articles selected were published in peer-reviewed journals. 
They were selected based on their relevance to the question asked and on their assessment of 
patient-oriented outcomes (POEMs). Inclusion criteria were studies that were randomized 
controlled trials (RCTs) published from 2007 to 2017 and not involved in Cochrane database 
systematic reviews or meta-analyses. Exclusion criteria were studies that evaluated populations 
older than 3 years or premature infants. The statistics reported in the selected studies were t test, 
Poisson test, p value, and negative binomial linear regression models. 
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The population evaluated in these studies included infants and toddlers of ages ranging 
from 0 to 18 months. The three randomized, double-blind, placebo-controlled trials used in this 
review studied the effect of bLF supplementation on patients of this age group. Chen et al. 
administered either a 35.8 mg dose of bLF per day to an experimental group or a visually 
matched placebo to a control group, while using an exclusively breastfed group of infants as a 
reference. The trial lasted for 3 months. In a study by King et al. patients in a treatment group 
were given Similac formula supplemented with 850 mg/L of bLF, and patients in a comparison 
group received the same Similac formula, but with 102 mg/L of bLF in it. The intervention lasted 
for 12 months. Ochoa et al. administered either 1,000 mg/day of bLF or placebo over a period of 
6 months. The outcome of interest included the effectiveness of bLF as a preventative measure in 
decreasing the incidence of diarrhea in infants and toddlers. 
Table 1: Demographics and Characteristics of Included Studies 
 
Study Type #Pts Age 
(mths) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Chen8 
(2016) 
RCT 359 4-6 Apparent good 
health, Hb > 60 
g/L, CRP < 
10mg/L, 
parent/guardian 
approval for 
participating in all 
aspects of study 
and their 
agreement to 
avoid using other 
iron-fortified 
formulas or foods 
History of severe, 
persistent, or 
chronic diarrhea; 
severe malnutrition; 
severe infections; 
serious chronic 
illness; 
personal/family 
history of allergy to 
cow’s milk or 
infant formula; 
eczema; allergic 
rhinitis; or asthma 
43 35.8 mg/day 
dose of 
bovine 
lactoferrin in 
infant 
formula 
King7 
(2007) 
RCT 79 0-12  Healthy infants 0-
4 weeks old, born 
at >34 wk of 
gestation and 
weighed >2000g, 
strictly bottle fed, 
staying in area for 
Intolerance to 
cow’s milk 
formula, major 
congenital 
anomalies, 
immunodeficiency, 
HIV-infected 
27 850 mg/L of 
bovine 
lactoferrin in 
infant 
formula 
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at least 1 year, 
guardians had 
access to 
telephone 
mother, parental 
inability to follow 
protocol 
Ochoa9 
(2013) 
RCT 555 12-18 Previously 
weaned 12-18-mo 
children 
History of severe, 
persistent, or 
chronic diarrhea; 
severe malnutrition; 
severe infections; 
serious chronic 
illness; 
personal/family 
history of allergy to 
cow’s milk or 
infant formula; 
eczema; allergic 
rhinitis; or asthma 
65 1,000 
mg/day of 
bovine 
lactoferrin as 
a food 
supplement 
 
Outcomes measured:  
Chen et al.8 measured the effectiveness of bLF as compared to placebo in decreasing 
morbidity of diarrhea in 4- to 6-months-old infants. Caregivers were given a standardized 
checklist of symptoms to refer to when reporting an occurrence of a morbidity episode. They 
were requested to notify healthcare workers if their infants had exhibited any of the symptoms 
from the list, including diarrhea. Data were analyzed using negative binomial regression models 
that estimated the incidence rate of diarrhea, thereby evaluating the effectiveness of bLF in 
decreasing its morbidity. The models were adjusted for the covariables of age and sex. 
 Ochoa et al.9 measured the effect of bLF on diarrheal prevention in 12- to 18-months-old 
toddlers. Previously trained community health workers performed daily home visits to administer 
coded bLF or placebo and to collect data on occurrence of diarrhea. Data were analyzed using 
Poisson test and Student t test to measure the incidence rate of diarrhea. King et al.7 measured 
the effect of bLF on occurrence of diarrhea in infants 0 to 12 months old. The caregivers were 
contacted every 1 to 2 weeks via telephone or personally to inquire about any symptoms of 
Toganov, Bovine Lactoferrin and Diarrhea 5 
diarrhea in their infants. The diagnosis of diarrhea was made by a pediatric nurse practitioner 
based on parental recollection and medical records from an attended clinic or hospital. Student t 
test was used to analyze the data and compare the incidence rate of diarrhea between infants who 
received bLF and those who received placebo. 
Results:  
Three studies compared the effect of bLF to placebo in infants and toddlers. Chen et al.8 
conducted their randomized controlled double-blind study in Chengdu City in western China 
from March 2012 to March 2013. They recruited 260 full-term infants 4 to 6 months of age who 
had been previously exclusively breastfed and were switching to formula feeding at that time. 
Additionally, 130 exclusively breastfed infants were recruited at the same time to be followed as 
a reference group. Inclusion and exclusion criteria are listed in Table 1. Three hundred and 
ninety infants met the inclusion criteria, and 31 were excluded because of their caregivers’ 
refusal to enroll in the study. Formula that contained 38 mg/100 g of bLF was randomly assigned 
to eligible infants, and the average daily bLF intake was estimated to be 35.8 mg/day. The 
control group received bLF-free formula that was comparable in its nutrient content to the bLF-
fortified formula. Both formulas were provided for free. 
Compliance with the formula was evaluated using data from recording tables on which 
caregivers included the number of spoons of formula their infants consumed per day. Field 
workers distributed both formulas, supervised their consumption, and visited the families every 
weekend to evaluate the amount of formula intake. Over the course of the study, 5 of the infants 
were rejected because their caregivers used other formula. Caregivers of 22 infants lost the 
recorded data, and caregivers of 15 breastfed infants were supplementing with formula, thus 
leading to their subsequent rejection. One infant was lost to the study as a result of formula 
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allergy. Altogether, these losses represented 12% of the sample size and were reported as 
dropouts.  
The incidence of diarrheal episodes per 100 child days in the bLF group was 0.57, 
whereas in the control group the incidence was 0.90; the number of diarrheal events was 59 and 
79, respectively (Table 2). The reference group of exclusively breastfed infants had 55 diarrheal 
events, and the incidence of diarrheal episodes was 0.60. The rate ratio of diarrheal occurrence 
between infants who received bLF and infants who received placebo was 0.32, with a 95% CI 
(0.20 - 0.72) and p < 0.05 (Table 3). The rate ratio between the breastfed group and the control 
group was 0.30, with a 95% CI (0.18 - 0.69) and p <0.05. Finally, the rate ratio between the bLF 
group and breastfed group was 1.12, with a 95% CI (0.71 - 1.89) and p < 0.05. These values 
illustrate a significant difference between the bLF and control groups and no significant 
difference between the bLF and breastfed groups of infants. 
Table 2. Incidence of Diarrheal Episodes from Chen et al.8 
Groups Diarrhea events Incidence/100 child days 
bLF  59 0.57 
Control   79 0.90 
Breastfed 55 0.60 
 
Table 3. Rate Ratios of Diarrheal Occurrence from Chen et al.8 
Groups Rate ratio 95% CI p value 
bLF/Control 0.32 (0.20 - 0.72) < 0.05 
Breastfed/Control 0.30 (0.18 - 0.69) < 0.05 
bLF/Breastfed 1.12 (0.71 - 1.89) > 0.05 
 
Ochoa et al.9 conducted their community-based, randomized, double-blind, controlled 
trial in Lima, Peru, from January 2008 to May 2011. They included 555 and excluded 3,119 
toddlers 12 to 18 months of age. The inclusion and exclusion criteria are included in Table 1. 
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Some toddlers were excluded because they were still being breastfed, caregivers of others 
refused to participate, and some fell under the exclusion criteria. Community health workers 
visited each family 6 days a week, twice a day to administer coded preparations of bLf or 
placebo and thereby to ensure compliance with the protocol. The participants consumed 0.5 g of 
bLF or placebo diluted in 25 mL of water 2 times a day.  
Between both groups, 32 children were noncompliant with protocol and were excluded 
from the study. From the bLF and placebo groups respectively, 25 and 40 children dropped out 
for a number of reasons. The compliance of the study was estimated to be 92% for administered 
doses, 90% for monthly clinic visits, and 98% for home visits. The incidence rate of diarrhea was 
5.4 and 5.2 episodes/child/year in the bLF and control groups, respectively (Table 4). The rate 
ratio for diarrhea occurrence between children who received bLF and children who received 
placebo was 1.05, with 95% CI (0.94 - 1.18) and p = 0.375. Therefore, no significant difference 
in incidence of diarrhea was noted between the bLF and control groups. 
Table 4. Incidence Rates and Rate Ratio of Diarrheal Occurrence from Ochoa et al.9 
Groups Incidence rate 
(episodes/child/year) 
95% CI p value 
bLF 5.43 (5.02 - 5.86) N/A 
Control 5.15 (4.74 - 5.59) N/A 
Rate ratio/comparison 1.05 (0.94 - 1.18) 0.375 
 
King et al.7 recruited their participants from newborn nursery and from outpatient clinic 
at the University of Maryland Medical System in Baltimore. They excluded infants with 
intolerance to cow’s milk formula, with major congenital abnormalities, with immunodeficiency, 
with HIV-infected mothers, or with caregivers unable to follow the protocol (Table 1). Seventy-
nine infants who were 0 to 4 weeks old, weighed >2,000 g, and were strictly bottle-fed enrolled 
in the study and were randomized to receive powdered Similac formula with or without added 
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bLF. The intervention and comparison preparations contained 850 mg/L and 102 mg/L of bLF, 
respectively. Both groups received formulas free of charge. 
The caregivers received formula every 1 to 2 months, and its distribution was recorded to 
monitor compliance. Compliance with formula intake was found to be excellent. Approximately 
33 oz of mixed formula per day were consumed by participants from both groups throughout the 
year. However, 27 of 79 infants dropped out from the study for a variety of reasons, and 13 of 
those who dropped out were from bLF group. No significant difference in incidence of diarrhea 
was noted between bLF and comparison groups. The episodes of diarrhea per infant-year were 
1.31 and 1.35 in the bLF and comparison groups, respectively (Table 5). All three studies found 
bLF to be safe in infants and toddlers, and no adverse events or intolerance to its effects were 
observed in any of the participants.7-9 
Table 5. Incidence of Diarrhea from King et al.7 
Groups Episodes/infant-year 
bLF 1.31 
Control 1.35 
 
Discussion:  
The immunomodulatory, antibacterial, and antiviral effects of LF have been studied 
multiple times in the past with both bovine and recombinant human analogs. A systematic 
review from Cochrane Library concluded that bLF might be effective in preventing late-onset 
sepsis and necrotizing enterocolitis in neonates, although it considered the evidence to be of low 
quality.10 The Food and Drug Administration (FDA) found both recombinant human LF and 
bovine LF to be safe for consumption.11,12   
Two of the three studies determined that bLF had no significant effect on diarrheal 
prevention in the evaluated age groups.7,9 King et al.7 conducted their trial with a relatively small 
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number of participants and evaluated a large number of variables/outcomes, possibly leading to 
an occurrence of Type II error. Additionally, because the caregivers were contacted once every 1 
to 2 weeks, they could have forgotten to report some episodes of diarrhea to the researchers. 
King et al.7 did not provide p values or 95% CIs in their study, thus leading to questions 
regarding the quality of their evidence. 
Although Ochoa et al.9 conducted the study with a relatively large sample size, they also 
evaluated a significant number of variables/outcomes. Another limitation was the use of a single 
dose of bLF (1,000 mg/day), potentially too low for that age group.9 Frequent home visits and 
health monitoring of participants might have improved their health risks and resulted in 
decreased incidence rates of diarrhea than it would have been in the absence of the study. The 
age range of the participants might have been too narrow, and different results might have been 
possible if the study included other age groups. Lastly, enteropathogens in Peru were different 
from those in some other parts of the world, and the frequency of children’s exposure to them 
might have increased pathogen-specific immunity and led to lessening of effects from bLF.9  
 Chen et al.8 found bLF to be effective in diarrheal prevention and demonstrated a 
statistically significant difference in incidence rate of diarrhea between bLF and placebo groups, 
as well as almost identical results between bLF and breastfed groups. Limitations of the study 
had some similarities to those in Ochoa et al., such as narrow age range of participants; only one 
dose of bLF tested (35.8 mg/day), which was potentially too low; and frequent home health 
educational interventions possibly modifying risks of diarrhea. Additionally, some bias might 
have been introduced in two of the studies, because formula was provided for free.7,8 Lastly, the 
participants who did not follow the rules of the study were subsequently excluded from the 
analysis of the data and reported as dropouts, possibly causing the final results to appear better 
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than they would have been. Performing a worst-case analysis of the data would have been a more 
honest way to evaluate the outcomes. 
As for the limitations of this EBM review, few randomized, double-blind, controlled 
trials that evaluate the effectiveness of bLF on diarrheal prevention are currently available. Also, 
age groups and doses of bLF vary significantly among the studies that are included in this 
review. Additionally, the differences in metabolism and in physiological development of 
newborns and 18-month-old infants are substantial and are important to take note of when 
answering the proposed question. 
Conclusion:  
The evidence whether bLF is effective in preventing diarrhea in infants and toddlers is 
conflicting. It appeared to be clinically effective in a single study with 4- to 6-months-old infants 
who were followed over a 3-months period, but had shown no effect in 0- to 12- and 12- to 18-
months-old infants and toddlers who were followed for 12 and 6 months, respectively.7-9 
Therefore, the effectiveness of bLF demonstrated by Chen et al.8 could have been influenced in 
some way by the short duration of the study and by the especially narrow age group.  
All three studies evaluated a large number of variables, and in two of them, diarrhea was 
not the primary outcome of the research.7-9 Conducting a trial that focused on incidence rate of 
diarrhea in a narrow age group of infants or toddlers would be beneficial. Also, studying more 
than one dose of bLF in the same trial and increasing the doses as the participants grew would be 
useful. Doing so would leave less room for questioning whether a specific dose of bLF was most 
effective in diarrheal prevention for the evaluated age group. Additionally, wider range of the 
doses would provide the evidence is of a better quality. 
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